Where Might Inovio Shares Land Post-Breakout? (INO)

Uploaded by Program Studi Sistem Informasi UMN on May 26, 2017 at 5:51 pm

Where Might Inovio Shares Land Post-Breakout? (INO)

Where Might Inovio Shares Land Post-Breakout? (INO)Investors had been growing impatient with the company after a pivotal Phase III study of VGX-3100 for cervical dysplasia was delayed by the Food & Drug Administration, whilethe Trump Administration’s plans to defund public health initiatives could have an adverse impact on its Ebola, Zika, and MERS-related products that rely on such funding.The response rate are also consistent with data from its Ebola, Zika,and MERS clinical trials in terms of demonstrating a 100% vaccine response with a very favorable safety profile.The favorable clinical data supports the company’s longer bullish case,but long-term investors must still contend with uncertainty in the VGX-3100 program and the potential need for additional capital before commercializing its major programs.From a technical standpoint, the stock broke out from its upper trend line resistanceand 200-day moving average at around $7.38 to about $12.00 before falling to prior highs at around $8.50.Inovio Pharmaceuticals Inc. (INO) soared more than 20% after reporting a nearly 100% immune response rate in its HIV vaccine candidate PENNVAX®-GP.

Where Might Inovio Shares Land Post-Breakout? (INO)Investors had been growing impatient with the company after a pivotal Phase III study of VGX-3100 for cervical dysplasia was delayed by the Food & Drug Administration, whilethe Trump Administration’s plans to defund public health initiatives could have an adverse impact on its Ebola, Zika, and MERS-related products that rely on such funding.The response rate are also consistent with data from its Ebola, Zika,and MERS clinical trials in terms of demonstrating a 100% vaccine response with a very favorable safety profile.The favorable clinical data supports the company’s longer bullish case,but long-term investors must still contend with uncertainty in the VGX-3100 program and the potential need for additional capital before commercializing its major programs.From a technical standpoint, the stock broke out from its upper trend line resistanceand 200-day moving average at around $7.38 to about $12.00 before falling to prior highs at around $8.50.Inovio Pharmaceuticals Inc. (INO) soared more than 20% after reporting a nearly 100% immune response rate in its HIV vaccine candidate PENNVAX®-GP.